IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt, Sergio1; Garderet, Laurent2; Durie, Brian3; Cook, Gordon4; Gahrton, Gosta5; Bruno, Benedetto6; Hari, Paremesweran7; Lokhorst, Henk8; McCarthy, Phillip9; Krishnan, Amrita10; Sonneveld, Pieter11; Goldschmidt, Harmut12; Jagannath, Sundar13; Barlogie, Bart13; Mateos, Maria14; Gimsing, Peter15; Sezer, Orhan16; Mikhael, Joseph17; Lu, Jin18; Dimopoulos, Meletios19; Mazumder, Amitabha20; Palumbo, Antonio21; Abonour, Rafat22; Anderson, Kenneth23; Attal, Michel24; Blade, Joan25; Bird, Jenny26; Cavo, Michele27; Comenzo, Raymond28; de la Rubia, Javier29; Einsele, Hermann30; Garcia-Sanz, Ramon14; Hillengass, Jens12; Holstein, Sarah9; Johnsen, Hans Erik31; Joshua, Douglas32; Koehne, Guenther1; Kumar, Shaji33; Kyle, Robert33; Leleu, Xavier34; Lonial, Sagar35; Ludwig, Heinz36; Nahi, Hareth5; Nooka, Anil35; Orlowski, Robert37; Rajkumar, Vincent33; Reiman, Anthony38; Richardson, Paul23; Riva, Eloisa39; Miguel, Jesus San40; Turreson, Ingemar41; Usmani, Saad42; Vesole, David43; Bensinger, William44; Qazilbash, Muzaffer37; Efebera, Yvonne45; Mohty, Mohamed46; Gasparreto, Christina47; Gajewski, James48; LeMaistre, Charles F.49; Bredeson, Chris50; Moreau, Phillipe51; Pasquini, Marcelo7; Kroeger, Nicolaus52; Stadtmauer, Edward53
关键词Myeloma Stem cell transplantation Salvage therapy
刊名BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
2015-12-01
DOI10.1016/j.bbmt.2015.09.016
21期:12页:2039-2051
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology ; Immunology ; Transplantation
研究领域[WOS]Hematology ; Immunology ; Transplantation
关键词[WOS]LENALIDOMIDE PLUS DEXAMETHASONE ; BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE ; LOW-DOSE DEXAMETHASONE ; RANDOMIZED PHASE-III ; AUTOLOGOUS TRANSPLANTATION ; ALLOGENEIC TRANSPLANTATION ; COMBINATION THERAPY ; FOLLOW-UP ; MAINTENANCE ; PROGRESSION
英文摘要

In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous Ha consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be performed to define the role of salvage autologous HCT in patients with MM relapsing after primary therapy comparing it to "best non-HCT therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding allogeneic Ha, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be performed in the context of a clinical trial if possible; (3) The role of postallogeneic Ha maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in patients with MM relapsing after primary therapy. (c) 2015 American Society for Blood and Marrow Transplantation.

语种英语
WOS记录号WOS:000364981700003
项目编号U10HL069294 ; U10HL069294 ; U10HL069294
资助机构Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute ; Blood and Marrow Transplant Clinical Trials Network from National Cancer Institute ; Be The Match Foundation ; SANOFI Corporation
引用统计
被引频次:43[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63391
专题北京大学第二临床医学院_血液科
作者单位1.Klin Univ Wurzburg, Wurzburg, Germany
2.Univ Hamburg Hosp, Hamburg, Germany
3.Aalborg Univ Hosp, Aalborg, Denmark
4.Mayo Clin Rochester, Rochester, MN USA
5.Hosp Claude Huriez, Lille, France
6.Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
7.Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
8.Wilhelminenkrebsforsch Inst, Vienna, Austria
9.Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
10.Dalhousie Univ, Sch Med, Dalhousie, NS, Canada
11.Hosp Clin Montevideo, Montevideo, Uruguay
12.Univ Navarra Clin, Navarra, Spain
13.Skane Univ Hosp, Malmo, Sweden
14.Levine Canc Inst, Charlotte, NC USA
15.John Theurer Canc Ctr, Hackensack, NJ USA
16.Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
17.Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
18.Univ Paris 06, Hosp St Antoine, Paris, France
19.IDIBAPS, Hosp Clin, Barcelona, Spain
20.Univ Hosp Bristol, Bristol, Avon, England
21.Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
22.Duke Univ Hosp, Durham, NC USA
23.Oregon Hlth & Sci Univ, Portland, OR USA
24.Sarah Cannon Res Inst, Nashville, TN USA
25.Ottawa Hosp Res Inst, Ottawa, ON, Canada
26.Univ Hosp Nantes, Nantes, France
27.Tufts Univ, Sch Med, Boston, MA 02111 USA
28.Hosp Dr Pesset, Valencia, Spain
29.Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY 10065 USA
30.Hop St Antoine, INSERM, UMRS 938, F-75571 Paris, France
31.Int Myeloma Fdn, Los Angeles, CA USA
32.St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
33.Karolinska Inst, Huddinge, Sweden
34.Univ Turin, Turin, Italy
35.Med Coll Wisconsin, Milwaukee, WI 53226 USA
36.Univ Med Ctr Utrecht, Utrecht, Netherlands
37.Roswell Pk Canc Inst, Buffalo, NY 14263 USA
38.City Hope Canc Ctr Duarte, Duarte, CA USA
39.Erasmus MC, Rotterdam, Netherlands
40.Heidelberg Univ, Heidelberg, Germany
41.Mt Sinai Sch Med, New York, NY USA
42.Hosp Univ Salamanca, Salamanca, Spain
43.Rigshosp, DK-2100 Copenhagen, Denmark
44.Mem Sisli Hastanesi, Istanbul, Turkey
45.Mayo Clin, Scottsdale, AZ USA
46.Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100871, Peoples R China
47.Univ Athens, Alexandra Hosp, Athens 11528, Greece
48.NYU, Sch Med, New York, NY USA
49.Univ Turin, Turin, Italy
50.Inst Claudius Regaud, Toulouse, France
51.Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
52.Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
53.Univ Sydney, Sch Med, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia
推荐引用方式
GB/T 7714
Giralt, Sergio,Garderet, Laurent,Durie, Brian,et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2015,21(12):2039-2051.
APA Giralt, Sergio.,Garderet, Laurent.,Durie, Brian.,Cook, Gordon.,Gahrton, Gosta.,...&Stadtmauer, Edward.(2015).American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,21(12),2039-2051.
MLA Giralt, Sergio,et al."American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma".BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 21.12(2015):2039-2051.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Giralt, Sergio]的文章
[Garderet, Laurent]的文章
[Durie, Brian]的文章
百度学术
百度学术中相似的文章
[Giralt, Sergio]的文章
[Garderet, Laurent]的文章
[Durie, Brian]的文章
必应学术
必应学术中相似的文章
[Giralt, Sergio]的文章
[Garderet, Laurent]的文章
[Durie, Brian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。